|
시장보고서
상품코드
2008006
폐표면활성제 시장 : 유형별, 약제 유형별, 적응증별, 투여 경로별, 유통 채널별, 지역별Pulmonary Surfactant Market, By Type, By Drug Type, By Indications, By Route of Administration, By Distribution Channel, By Geography |
||||||
폐표면활성제 시장은 2026년에 7억 2,320만 달러로 추정되고 있으며, 2033년까지 9억 4,780만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 7억 2,320만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 7.20% | 2033년 시장 규모 예측 : | 9억 4,780만 달러 |
폐표면활성제는 지질과 단백질로 구성된 복잡하고 높은 계면활성도를 가진 물질로 폐의 폐포 표면을 덮고 있는 액체에 존재합니다. 표면 활성 물질은 폐의 생리적 기능에서 매우 중요한 역할을 합니다. 주요 생물물리학적 기능은 폐 용량이 낮은 상태에서 폐포의 허탈을 방지하고, 정상 및 강제 호흡시 세기관지의 개방성을 유지하는 것이며, 주요 비생물물리학적 및 면역학적 기능은 흡입된 입자와 미생물에 의한 손상 및 감염으로부터 폐를 보호하는 것입니다. 폐표면활성제는 생화학적 조성, 형태학적 조직 및 특정 생물 물리학적 기능 측면에서 불균일합니다. 계면활성제는 폐활량이 낮은 상태에서 폐포의 허탈을 방지하고, 폐활량 감소를 방지하며
또한 흡입된 입자나 미생물에 의한 손상이나 감염으로부터 폐를 보호하는 역할도 한다(면역학적, 비생물학적 기능). 폐표면활성제는 세척법에 의해만 채취할 수 있지만, 이 방법은 기존의 생물 물리학적 및 생화학적 미세 구조가 파괴될 수 있습니다. 폐표면활성제에 대한 ex vivo 연구를 해석할 때는 항상 이러한 한계를 고려해야 합니다.
시장 역학
일부 호흡기 감염 및 호흡기 질환의 유병률 증가는 예측 기간 중 글로벌 폐 표면 활성제 시장을 촉진할 것으로 예상됩니다. 예를 들어 2022년 5월 20일 기준 전 세계에서 보고된 COPD(만성폐쇄성폐질환)로 인한 사망의 90%는 70세 미만 환자에서 발생하며, 인도, 한국, 방글라데시 등 중저소득국가(LMIC)에서 발생합니다. 만성폐쇄성폐질환(COPD)은 전 세계 주요 사망 원인 중 하나이며, 2019년 323만 명이 사망했습니다.
신규 치료제 승인 건수의 증가는 글로벌 폐표면활성제 시장의 성장을 이끄는 주요 요인 중 하나입니다. 예를 들어 2020년 7월 베링거인겔하임은 유럽위원회(EC)가 특발성 폐섬유증(IPF)을 넘어 진행성 표현형을 보이는 기타 만성 섬유화 간질성 폐질환(ILD) 치료제로서 성인용 닌테다닙의 추가 적응증을 승인했다고 발표했습니다. 이번 승인은 2020년 5월 유럽의약품위원회(CHMP)가 긍정적인 견해를 밝힌 데 따른 것입니다. 미국 식품의약국(FDA), 캐나다 보건부, 일본 의약품의료기기종합기구(PMDA)도 비슷한 환자군에 대한 치료제로 닌테다닙을 승인했습니다. 이번 승인은 진행성 만성 섬유화 간질성 폐질환(ILD) 환자에서 닌테다닙의 유효성, 안전성 및 내약성을 평가한 무작위, 이중맹검, 위약 대조, 병렬군 간 3상 임상 3상 시험인 INBUILD 연구 결과를 바탕으로 이뤄졌다.
본 시험의 주요 특징.
- 이 보고서는 2021년을 기준연도로 하여 예측 기간(2022-2030년) 시장 규모를 제시하는 글로벌 폐표면활성제 시장에 대한 상세한 분석을 제공합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 지역적 확장, 유통 전략, 주요 개발 및 전략, 향후 계획 등 다양한 매개 변수를 기반으로 세계의 폐 표면 활성제 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 폐표면활성제 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 폐표면활성제 시장 : 유형별, 2026-2033년
제5장 세계의 폐표면활성제 시장 : 약제 유형별, 2026-2033년
제6장 세계의 폐표면활성제 시장 : 적응증별, 2026-2033년
제7장 세계의 폐표면활성제 시장 : 투여 경로별, 2026-2033년
제8장 세계의 폐표면활성제 시장 : 유통 채널별, 2026-2033년
제9장 세계의 폐표면활성제 시장 : 지역별, 2026-2033년
제10장 경쟁 구도
제11장 섹션
KSAPulmonary Surfactant Market is estimated to be valued at USD 723.2 Mn in 2026 and is expected to reach USD 947.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 723.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 947.8 Mn |
Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It's major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it's major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves
bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant.
Market Dynamics
Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019.
Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.
Key features of the study
- This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global pulmonary surfactant market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant
Market Segmentation
- By Type
- Synthetic Pulmonary Surfactant
- Animal Derived Surfactant
- By Drug Type
- Poractant alfa
- Lucinactant
- Calfactant
- By Indications
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Obstructive lung Diseases
- Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
- By Route of Administration
- Intratracheal
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Boehinger Ingelheim
- AbbVie Inc
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima (Noargen)
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Indications
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Industry Trend
- New Product Approvals/Launch
- Merger and Acquisitions
- PEST Analysis
4. Global Pulmonary Surfactant Market, By Type, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Synthetic Pulmonary Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Animal Derived Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Global Pulmonary Surfactant Market, By Drug Type, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Poractant alfa
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Lucinactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Calfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Pulmonary Surfactant Market, By Indications, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Respiratory Distress Syndrome (RDS)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Respiratory Infections
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Obstructive lung Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
7. Global Pulmonary Surfactant Market, By Route of Administration, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Intratracheal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
8. Global Pulmonary Surfactant Market, By Distribution Channel, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
9. Global Pulmonary Surfactant Market, By Region, 2026 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Chiesi Farmaceutici
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ONY Biotech Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lyomark Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Aviva Systems Biology Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Windtree Therapeutics, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Tekzima (Noargen)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Biomatik
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Nanjing Norris Pharm Technology
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Reddot Biotech
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About Us
